Dr. Perlis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
15 Parkman Street Wac 812
Psychiatry Outpatient Department
Boston, MA 02114Phone+1 617-724-5600Fax+1 617-724-3028
Education & Training
- Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 1997 - 2001
- Massachusetts General HospitalInternship, Internal Medicine, 1997 - 1998
- Harvard Medical SchoolClass of 1997
Certifications & Licensure
- MA State Medical License 1998 - 2026
- American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- Effectiveness of Pramipexole for Treatment-Resistant Depression Start of enrollment: 2003 Sep 01
- Simvastatin Augmentation of Lithium Treatment in Bipolar Depression Start of enrollment: 2012 Aug 01
- Adjunctive Isradipine for the Treatment of Bipolar Depression Start of enrollment: 2013 Feb 01
Publications & Presentations
PubMed
- Health Systems Are Struggling to Keep Up With AI-A National Registration System Could Help.Roy Perlis, Rita Rubin
JAMA. 2024-12-20 - FDA Commissioner Robert Califf on Setting Guardrails for AI in Health Care.Roy Perlis, Jennifer Abbasi
JAMA. 2024-12-17 - 2 citationsDimensional Measures of Psychopathology in Children and Adolescents Using Large Language Models.Thomas H McCoy Jr, Roy H Perlis
Biological Psychiatry. 2024-12-15
Journal Articles
- Psychiatry and COVID-19Roy Perlis, Donald Goff, JAMA
- Can Electronic Health Records Revive Central Nervous System Clinical Trials?Maurizio Fava, Roy H Perlis, Nature
- Temporal Trends and Characteristics of Reportable Health Data Breaches, 2010-2017Roy Perlis, MD, JAMA
Lectures
- Effect of Cytochrome CYP2C19 Metabolizing Activity on Antidepressant Response and Side Effects: Meta-Analysis of Data from Genome-Wide Association Studies162nd Annual Meeting, San Francisco, California, USA
- Discovery of a Highly Selective Glycogen Synthase Kinase‐3 Inhibitor (PF‐04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET NeuroimagingAmerican Psychiatric Association, 162nd Annual Meeting, San Francisco, California, USA
Authored Content
- The Time Has Come for Over-the-Counter AntidepressantsApril 2024
- Genome-Wide Association Study of Dimensional Psychopathology Using Electronic Health RecordsFebruary 2018
- High Throughput Phenotyping for Dimensional Psychopathology in Electronic Health RecordsFebruary 2018
Press Mentions
- What Happens When AI Is Used to Recommend Treatments for Patients with Bipolar Disorder?September 16th, 2024
- Trust in Physicians and Hospitals During the COVID-19 Pandemic in a 50-State Survey of US AdultsAugust 26th, 2024
- Benchmarks: Mass General Research News and Notes for August 9, 2024August 9th, 2024
- Join now to see all
Grant Support
- In Vitro And In Vivo Study Of Simvastatin PLUS Lithium In Bipolar DepressionNational Institute Of Mental Health2012
- Building A Risk Stratification Model For Treatment Resistance In Major DepressiveNational Institute Of Mental Health2009–2011
- Pramipexole In Treatment-Resistant DepressionNational Institute Of Mental Health2003–2007
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: